Dr. Cindy Xiong joined Foresite Capital in 2019 as a member of the investment team, focusing on evaluating investment opportunities of private and public biotech companies. Cindy serves on the boards of ImmPACT Bio (board director), Raythera (board observer), Remix Therapeutics (board observer) and Xinthera (board observer, acquired by Gilead).
Prior to Foresite, Cindy earned her MBA in Healthcare Management from the Wharton school. During her time at Wharton, she interned at Lilly Asia Ventures and was a summer analyst at Tybourne Capital. Cindy received her PhD in Biology from the University of Michigan, Ann Arbor, where she studied neural regeneration and degeneration post axonal injury. After that, she was a Helen Hay Whitney postdoctoral fellow with Dr. Wendell Lim at UCSF, developing new technologies for genome and cell engineering. She then joined Agenovir as the first scientist, where she led a team to develop CRISPR based therapeutics for HPV induced cancers.
